Showing results (241-250 of 317) with videos related to
Sort By:
Pageof 32
Proteomics. Clinical Applications|November 1, 2021
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelAAnneke D van Dijk, Fieke W Hoff, Yihua Qiu, et al.American Journal of Hematology|May 21, 2013
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology GroupRoland B Walter, George S Laszlo, Todd A Alonzo, et al.Pediatric Blood & Cancer|February 15, 2023
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology GroupKaren M Chisholm, Jenny Smith, Amy E Heerema-McKenney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.Blood|November 15, 2007
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology groupBeverly J Lange, Franklin O Smith, James Feusner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyLeslie Mortland, Todd A Alonzo, Roland B Walter, et al.Blood|April 27, 2016
Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup studyJasmijn D E de Rooij, Riccardo Masetti, Marry M van den Heuvel-Eibrink, et al.Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.Science Advances|August 17, 2022
Data for all: Tactile graphics that light up with picture-perfect resolutionJordan C Koone, Chad M Dashnaw, Emily A Alonzo, et al.Pageof 32